HIF1A and B-cell chronic lymphocytic leukemia: In line with these previous findings, here, we observed that the inhibition of HIF-1α regulatory pathways by simvastatin, idelalisib or PD98059 is paralleled by a reduction in CLL cells’ viability and an increased sensitivity to fludarabine.